Advances in epigenetic therapeutics with focus on solid tumors

Ning Jin; Tiffany L. George; Gregory A. Otterson; Claire Verschraegen; Haitao Wen; David Carbone; James Herman; Erin M. Bertino; Kai He

doi:10.1186/s13148-021-01069-7

Advances in epigenetic therapeutics with focus on solid tumors

Ning Jin, Tiffany L. George, Gregory A. Otterson, Claire Verschraegen, Haitao Wen, David Carbone, James Herman, Erin M. Bertino, Kai He

Research output: Contribution to journal › Review article › peer-review

81 Scopus citations

Abstract

Epigenetic (“above genetics”) modifications can alter the gene expression without altering the DNA sequence. Aberrant epigenetic regulations in cancer include DNA methylation, histone methylation, histone acetylation, non-coding RNA, and mRNA methylation. Epigenetic-targeted agents have demonstrated clinical activities in hematological malignancies and therapeutic potential in solid tumors. In this review, we describe mechanisms of various epigenetic modifications, discuss the Food and Drug Administration-approved epigenetic agents, and focus on the current clinical investigations of novel epigenetic monotherapies and combination therapies in solid tumors.

Original language	English
Article number	83
Journal	Clinical Epigenetics
Volume	13
Issue number	1
DOIs	https://doi.org/10.1186/s13148-021-01069-7
State	Published - Dec 2021

Keywords

Acetylation
Cancer
Epigenetic
Methylation
Reprogramming
Therapeutics
Therapies

Access to Document

10.1186/s13148-021-01069-7

Cite this

@article{50384238b3074631a90c56a2c7c6f233,

title = "Advances in epigenetic therapeutics with focus on solid tumors",

abstract = "Epigenetic (“above genetics”) modifications can alter the gene expression without altering the DNA sequence. Aberrant epigenetic regulations in cancer include DNA methylation, histone methylation, histone acetylation, non-coding RNA, and mRNA methylation. Epigenetic-targeted agents have demonstrated clinical activities in hematological malignancies and therapeutic potential in solid tumors. In this review, we describe mechanisms of various epigenetic modifications, discuss the Food and Drug Administration-approved epigenetic agents, and focus on the current clinical investigations of novel epigenetic monotherapies and combination therapies in solid tumors.",

keywords = "Acetylation, Cancer, Epigenetic, Methylation, Reprogramming, Therapeutics, Therapies",

author = "Ning Jin and George, {Tiffany L.} and Otterson, {Gregory A.} and Claire Verschraegen and Haitao Wen and David Carbone and James Herman and Bertino, {Erin M.} and Kai He",

note = "Publisher Copyright: {\textcopyright} 2021, The Author(s).",

year = "2021",

month = dec,

doi = "10.1186/s13148-021-01069-7",

language = "English",

volume = "13",

journal = "Clinical Epigenetics",

issn = "1868-7075",

number = "1",

}

TY - JOUR

T1 - Advances in epigenetic therapeutics with focus on solid tumors

AU - Jin, Ning

AU - George, Tiffany L.

AU - Otterson, Gregory A.

AU - Verschraegen, Claire

AU - Wen, Haitao

AU - Carbone, David

AU - Herman, James

AU - Bertino, Erin M.

AU - He, Kai

PY - 2021/12

Y1 - 2021/12

N2 - Epigenetic (“above genetics”) modifications can alter the gene expression without altering the DNA sequence. Aberrant epigenetic regulations in cancer include DNA methylation, histone methylation, histone acetylation, non-coding RNA, and mRNA methylation. Epigenetic-targeted agents have demonstrated clinical activities in hematological malignancies and therapeutic potential in solid tumors. In this review, we describe mechanisms of various epigenetic modifications, discuss the Food and Drug Administration-approved epigenetic agents, and focus on the current clinical investigations of novel epigenetic monotherapies and combination therapies in solid tumors.

AB - Epigenetic (“above genetics”) modifications can alter the gene expression without altering the DNA sequence. Aberrant epigenetic regulations in cancer include DNA methylation, histone methylation, histone acetylation, non-coding RNA, and mRNA methylation. Epigenetic-targeted agents have demonstrated clinical activities in hematological malignancies and therapeutic potential in solid tumors. In this review, we describe mechanisms of various epigenetic modifications, discuss the Food and Drug Administration-approved epigenetic agents, and focus on the current clinical investigations of novel epigenetic monotherapies and combination therapies in solid tumors.

KW - Acetylation

KW - Cancer

KW - Epigenetic

KW - Methylation

KW - Reprogramming

KW - Therapeutics

KW - Therapies

UR - http://www.scopus.com/inward/record.url?scp=85104499369&partnerID=8YFLogxK

U2 - 10.1186/s13148-021-01069-7

DO - 10.1186/s13148-021-01069-7

M3 - Review article

C2 - 33879235

AN - SCOPUS:85104499369

SN - 1868-7075

VL - 13

JO - Clinical Epigenetics

JF - Clinical Epigenetics

IS - 1

M1 - 83

ER -

Advances in epigenetic therapeutics with focus on solid tumors

Abstract

Keywords

Access to Document

Other files and links

Fingerprint

Cite this